The anti-inflammatory cytokine IL10 has long been proposed to limit intestinal inflammation, and genetically engineered IL-10 deficient mice develop spontaneous colitis suggesting it might serve as a therapeutic target for UC [27]. This evidence concerns the gene IL10 and colitis.